1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) - Concepedia

Concepedia

Publication | Open Access

1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

DOI Full Paper Access

10

Citations

0

References

2023

Year

Alison M. Schram, Kōichi Goto, Dongwook Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, K. Umemoto, Joon Oh Park, Natasha B. Leighl,

Annals of Oncology

No additional data available for this publication yet. Check back later!